Healthcare / BiotechnologyOTC Markets OTCQB
$0.21
-0.01 (-4.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-97.3M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$87M
P/E
N/A
•EV/EBITDA
N/A
•ROE
861.6%
↑Gross Margin
N/A
•Debt/Equity
-1.88
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+3.7%
FCF CAGR
—
FCF margin
-246.0%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $39.6M · net income $-122.9M · FCF $-97.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $39.6M | $39.6M | $57.8M | $176.2M | $111.3M | $110.7M | $118.2M | $102.4M | $84.5M | $36.6M | $19.4M | $39.5M | $45.9M | $24.1M | $21.7M | $10.3M | $20.8M | $22.2M |
| Net Income | $-122.9M | $-122.9M | $-97.9M | $-257.8M | $-192.3M | $-178.3M | $-121.0M | $-95.2M | $-68.3M | $-54.6M | $-71.7M | $-40.7M | $-26.4M | $-26.6M | $-22.3M | $-35.8M | $-24.9M | $-18.6M |
| EBITDA | $-100.4M | $-100.4M | $-89.1M | $-96.8M | $-180.7M | $-173.9M | $-123.9M | $-101.3M | $-74.8M | $-54.9M | $-71.6M | $-45.9M | $-26.2M | $-26.1M | $-21.5M | $-35.2M | $-24.3M | $-18.8M |
| EPS | -0.44 | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -273.1% | -273.1% | -170.3% | -67.5% | -180.8% | -165.6% | -109.6% | -102.7% | -91.4% | -154.1% | -374.2% | -118.5% | -58.4% | -110.7% | -102.5% | -347.1% | -119.9% | -87.4% |
| Net Margin | -310.8% | -310.8% | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% | -92.9% | -80.9% | -149.2% | -369.6% | -102.9% | -57.6% | -110.3% | -102.8% | -346.4% | -119.5% | -83.8% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | -1.88 | -1.88 | 1.34 | 0.46 | 0.15 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.70 | 0.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-97.3M | $-97.3M | $-67.4M | $-246.0M | $-243.8M | $-256.5M | $155.2M | $-165.1M | $-6.5M | $7.4M | $-66.6M | — | — | $-19.9M | $-8.8M | $-26.5M | $-24.6M | $-6.4M |
| Returns | ||||||||||||||||||
| ROE | 861.6% | 861.6% | -430.1% | -311.1% | -65.2% | -47.5% | -24.3% | -22.0% | -18.6% | -29.0% | -52.6% | -21.2% | -12.8% | -21.9% | -34.3% | -44.6% | -44.5% | -25.9% |
| Valuation | ||||||||||||||||||
| P/B | — | — | 11.52 | 0.95 | 1.73 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -31.6% | -31.6% | -67.2% | 58.3% | — | -6.3% | 15.4% | 21.3% | 131.0% | 88.6% | -51.0% | -13.8% | 90.1% | 11.4% | 109.9% | -50.4% | -6.2% | — |
| EPS Growth | 10.2% | 10.2% | 66.9% | -18.4% | — | -36.7% | -5.9% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.49 → -0.44
Residual
-55.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.